Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Dasabuvir Sodium

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dasabuvir Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208
    Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208

    14 Mar 2018

    // S. Owermohle PLATFORM

    https://platform.mi.spglobal.com/web/client?auth=inherit#news/article?id=43852931&cdid=A-43852931-11822

    S. Owermohle PLATFORM
    14 Mar 2018
    Share Share
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

    06 Jan 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report

    Angus Liu FIERCE PHARMA
    06 Jan 2018
    Share Share
    AbbVie's Q4 sales miss the mark as cancer, hep C meds lag
    AbbVie's Q4 sales miss the mark as cancer, hep C meds lag

    27 Jan 2017

    // Carly Helfand FIEREC PHARMA

    http://www.fiercepharma.com/pharma/abbvie-sees-top-line-miss-q4-thanks-to-lagging-cancer-hep-c-sales

    Carly Helfand FIEREC PHARMA
    27 Jan 2017
    Share Share
    Conitec Approves Incorporation by SUS of AbbVie's Drug for Chronic Hepatitis C
    Conitec Approves Incorporation by SUS of AbbVie's Drug for Chronic Hepatitis C

    05 Dec 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/conitec-aprova-incorporacao-pelo-sus-do-medicamento-da-abbvie-para-hepatite-c-cronica-604818136.html

    PR NEWSWIRE
    05 Dec 2016
    Share Share
    EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B
    EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B

    03 Dec 2016

    // VL Nathan REUTERS

    http://www.reuters.com/article/us-eu-hepatitis-idUSKBN13R1T7

    VL Nathan REUTERS
    03 Dec 2016
    Share Share
    AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C
    AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C

    22 Jul 2016

    // FDA

    https://www.pharmacompass.com/pdf/news/AbbVie-Receives-FDA-Approval-Of-Viekria-XR-For-The-Treatment-of-Genotype-1-Chronic-Hepatitis-C-1469863214.pdf

    FDA
    22 Jul 2016
    Share Share